p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia

Houmin Lin1,2, Steven Grant Dixon1, Wei Hu1

  • 1Department of Pathology and Laboratory Medicine, Medical University of South Carolina, 171 Ashley Avenue, MSC908, Charleston, SC, 29425, USA.

Insights

Amyloid beta (Aβ) triggers interleukin-6 (IL-6) production in human microglia via p38 MAPK activation. Targeting p38 MAPK may reduce Alzheimer's disease (AD) neuroinflammation.

Area of Science:

  • Neuroscience
  • Immunology
  • Molecular Biology

Background:

  • Alzheimer's disease (AD) is characterized by amyloid beta (Aβ) plaques and neuroinflammation.
  • Interleukin-6 (IL-6) expression is elevated in AD brains, but its regulation in microglia is unclear.

Purpose of the Study:

  • To investigate the mechanisms regulating IL-6 expression in human microglia in response to Aβ.
  • To determine the role of p38 mitogen-activated protein kinase (p38 MAPK) in Aβ-induced IL-6 production.

Main Methods:

  • HMC3 and THP-1 human microglial cells were treated with Aβ oligomers (Aβ40).
  • IL-6 and TNFα mRNA and protein levels were measured.
  • p38 MAPK activation was assessed, and its inhibition was tested using specific inhibitors (BIRB 796, SB202190).
  • Immunohistochemistry was performed on human AD and control brain specimens.

Main Results:

  • Aβ40 dose-dependently increased IL-6 expression and secretion in human microglia.
  • Aβ40 treatment elevated IL-6 and TNFα mRNA levels.
  • Aβ40-induced IL-6 production was dependent on p38 MAPK activation.
  • Inhibition of p38 MAPK blocked Aβ40-induced IL-6 release.
  • Elevated IL-6 and activated p38 MAPK were observed in microglia from AD patients, with co-localization in the cortex.

Conclusions:

  • p38 MAPK is a key regulator of Aβ-induced IL-6 production in human microglia.
  • Targeting p38 MAPK could be a therapeutic strategy for mitigating Aβ-driven neuroinflammation in Alzheimer's disease.